Search Within

Advanced Practice Providers

  1. "Dermatology Service"
Formats
  1. Meeting Abstract (17)
  2. Journal Article (10)
  3. Correspondence (1)
  4. Research Letter (1)
Groups
  1. Department of Medicine (29)
  2. Dermatology (29)
  3. Dermatology Service (29)
  4. Division of Subspecialty Medicine (29)
  5. Survivorship Research (19)
  6. Population Sciences Research Program (18)

More Groups

People
  1. Alison Moskowitz (15)
  2. Patricia Myskowski (15)
  3. Steven Horwitz (15)
  4. Natasha Galasso (11)
  5. Nivetha Ganesan (10)
  6. Ahmet Dogan (9)

More People

Years
  1. 2024 (4)
  2. 2023 (3)
  3. 2022 (5)
  4. 2021 (4)
  5. 2020 (3)
  6. 2019 (1)

More Years

Publications
  1. Blood (8)
  2. Journal of Clinical Oncology (4)
  3. Journal of the American Academy of Dermatology (3)
  4. Cancer Immunology Research (2)
  5. Hematological Oncology (2)
  6. American Journal of Hematology (1)

More Publications

Publishers
  1. American Society of Hematology (8)
  2. American Society of Clinical Oncology (4)
  3. American Association for Cancer Research (3)
  4. Mosby Elsevier (3)
  5. Elsevier Inc. (2)
  6. Wiley Blackwell (2)

More Publishers

Results (29)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The combination of duvelisib, a PI3K-δ,γ inhibitor, and romidepsin is highly active in relapsed/refractory peripheral T-cell lymphoma with low rates of transaminitis: Results of parallel multicenter, phase 1 combination studies with expansion cohorts
    Meeting Abstract

    Horwitz, S. M.; Moskowitz, A. J.; Jacobsen, E. D.; Mehta-Shah, N.; Khodadoust, M. S.; Fisher, D. C.; Myskowski, P.; Wang, E. B. K.; Tawa, M.; Davey, T.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Durable responses observed with JAK inhibition in T-cell lymphomas
    Meeting Abstract

    Moskowitz, A. J.; Jacobsen, E.; Ruan, J.; Schatz, J. H.; Obadi, O.; Motylinski, K.; Jarjies, C.; Galasso, N.; Hancock, H.; Davey, T.; more...
    Blood (2018)

    Fulltext@MSK | Save
  • Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC
    Journal Article

    Santini, F. C.; Rizvi, H.; Plodkowski, A. J.; Ni, A.; Lacouture, M. E.; Gambarin-Gelwan, M.; Wilkins, O.; Panora, E.; Halpenny, D. F.; Long, N. M.; more...
    Cancer Immunology Research (2018)

    Fulltext@MSK | Save
  • A phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory B-and T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M. A.; Lynch, P.; Scheuerman, M.; Minnal, V.; Galasso, N.; Kumar, A.; Gerecitano, J.; Zelenetz, A. D.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • In vitro, in vivo, and parallel phase I evidence support the safety and activity of duvelisib, a PI3K-δ,γ inhibitor, in combination with romidepsin or bortezomib in relapsed/refractory T-cell lymphoma
    Meeting Abstract

    Moskowitz, A. J.; Koch, R.; Mehta-Shah, N.; Myskowski, P.; Kheterpal, M.; Dogan, A.; Davey, T.; Galasso, N.; Evan, M.; Shah, M.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A Phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory T-cell lymphomas
    Meeting Abstract

    Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M.; Lynch, P.; Scheuerman, M.; Kumar, A.; Gerecitano, J. F.; Zelenetz, A. D.; Hamlin, P. A. Jr; Noy, A.; more...
    Blood (2016)

    Fulltext@MSK | Save
  • Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1
    Journal Article

    Naidoo, J.; Schindler, K.; Querfeld, C.; Busam, K.; Cunningham, J.; Page, D. B.; Postow, M. A.; Weinstein, A.; Lucas, A. S.; Ciccolini, K. T.; more...
    Cancer Immunology Research (2016)

    Fulltext@MSK | Save
  • A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Activity in T-cell lymphoma
    Meeting Abstract

    Mehta-Shah, N; Lunning, M. A.; Boruchov, A. M.; Ruan, J.; Nair, S.; Lynch, P.; Byrne, R.; Moskowitz, A. J.; Matasar, M. J.; Gerecitano, J. F.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: Phase I results
    Meeting Abstract

    Lunning, M. A.; Ruan, J.; Nair, S.; Boruchov, A. M.; Byrne, R.; Gerecitano, J. F.; Hamlin, P. A.; Inserra, B.; Leonard, J.; Lynch, P.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save